A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Gail J Roboz, MD
Weill Cornell Medical College - New York-Presbyterian Hospital
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Scripps Green Hospital
La Jolla, California, United States
David Hermel, MDRecruiting - Ucla Medical Center
Los Angeles, California, United States
Gary Schiller, MDRecruiting - Weill Cornell Medical College - Newyork-Presbyterian Hospital
New York, New York, United States
Recruiting - Md Anderson Cancer Center
Houston, Texas, United States
Maro Ohanian, D.O.Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 16 Aug 2022
- Primary completion
- 31 Mar 2027
- Completion
- 30 Sept 2027
- Last update posted
- 10 Mar 2025
- Registered enrollment
- 48
- Registry id
- NCT05190471
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.